Infectious diseases

Reven Publishes New COVID-19 Related Articles Outlining Clinical Impact Potential of Its RJX Platform

Tuesday, July 7, 2020 - 1:09pm

Ph.D., and other members of the Reven team and their academic collaborators in the medical journal, Clinical Investigation (London).

Key Points: 
  • Ph.D., and other members of the Reven team and their academic collaborators in the medical journal, Clinical Investigation (London).
  • The article also discusses the potential for the prevention of life-threatening complications from COVID-19 with RJX based on data obtained from clinical and non-clinical studies.
  • She provides the critical design elements for a two-cohort, two-part placebo-controlled, double-blind Phase 2 study of RJX in COVID-19 patients.
  • Clinical Impact Potential Of Rejuveinix (RJX) For Prevention Of Fatal Acute Respiratory Distress Syndrome (ARDS) And Multi-Organ Failure In Covid-19 Patients.

Bradley Corp. Shares Six Ways the Pandemic is Transforming Restroom Design

Tuesday, July 7, 2020 - 1:45pm

Companies, educational institutions and municipalities are all now evaluating new procedures and products for their restroom facilities.

Key Points: 
  • Companies, educational institutions and municipalities are all now evaluating new procedures and products for their restroom facilities.
  • The goal is to create safe and healthy indoor environments that reduce the spread of airborne and surface contaminants.
  • Automatic door openers typically seen to support accessible design are now also being implemented in locations to prevent hand-surface contact.
  • is a leading manufacturer of commercial plumbing fixtures, washroom accessories, restroom partitions, emergency fixtures and solid plastic lockers.

Walter Isaacson Interviews MIT President Emerita Susan Hockfield on Overcoming the COVID-19 “Diagnostics Deficit” and How Convergence of Biology and Technology Will Drive 21st Century Innovation

Tuesday, July 7, 2020 - 1:00pm

Dr. Hockfield is author of the new book The Living Machine: How Biology will Build the Next Technology Revolution.

Key Points: 
  • Dr. Hockfield is author of the new book The Living Machine: How Biology will Build the Next Technology Revolution.
  • From then on, I just discovered so many new technologies emerging from the convergence of biology with engineering and the hard sciences.
  • Its an exciting story and I think it is going to be the technology story of the 21st century.
  • The countries that have managed to control the coronavirus are countries that have been able to track and trace.

Cerus Corporation Reports Successful Inactivation of SARS-CoV-2 with the INTERCEPT Blood System for Plasma

Tuesday, July 7, 2020 - 1:30pm

Cerus Corporation (Nasdaq:CERS) announced today study results demonstrating that the INTERCEPT Blood System inactivates SARS-CoV-2, the causative agent for COVID-19, in plasma components intended for transfusion.

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) announced today study results demonstrating that the INTERCEPT Blood System inactivates SARS-CoV-2, the causative agent for COVID-19, in plasma components intended for transfusion.
  • The investigators are currently conducting a subsequent study to assess the ability of the INTERCEPT Blood System to inactivate SARS-CoV-2 in platelet components.
  • Cerus Corporation is dedicated solely to safeguarding the worlds blood supply and aims to become the preeminent global blood products company.
  • INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

QLess Digital Line Management Promotes Social Distancing for Retailers

Tuesday, July 7, 2020 - 4:00pm

QLess enables virtual check-ins through a dedicated online portal with real-time SMS updates about wait times and placements in line.

Key Points: 
  • QLess enables virtual check-ins through a dedicated online portal with real-time SMS updates about wait times and placements in line.
  • Our system is used by hundreds of organizations in many industries, and is perfectly positioned to help solve the logistics of social distancing.
  • Retailers that use QLess have also seen up to a 75 percent reduction in walk-aways.
  • For more information about solutions by QLess for customer interaction management in the retail industry, please visit http://info.qless.com/blog/qless-coronavirus-solutions .

The Pershing Square Foundation Awards $3 Million to Innovative SARS-CoV-2 Research Projects

Tuesday, July 7, 2020 - 2:34pm

The Pershing Square Foundation (the Foundation) today announced that it has awarded $3 million to nineteen recipients at ten academic research institutions conducting research related to the SARS-CoV-2 virus.

Key Points: 
  • The Pershing Square Foundation (the Foundation) today announced that it has awarded $3 million to nineteen recipients at ten academic research institutions conducting research related to the SARS-CoV-2 virus.
  • Since 2013, the Pershing Square Sohn Cancer Research Alliance has awarded over $22 million to 39 talented scientists.
  • The Pershing Square Sohn Cancer Research Alliance was formed in 2013 through a $25 million commitment by The Pershing Square Foundation, which partnered with The Sohn Conference Foundation.
  • Annually, the Alliance awards the Pershing Square Sohn Prize to young New York based scientists who are engaged in cutting-edge cancer research.

CytoAgents Receives Funding to Accelerate COVID-19 Clinical Trials for Cytokine Storm Treatment From Richard King Mellon Foundation

Tuesday, July 7, 2020 - 1:58pm

One of our goals is to seed quick solutions to the communitys most immediate healthcare needs, said Sam Reiman, Director of the Richard King Mellon Foundation.

Key Points: 
  • One of our goals is to seed quick solutions to the communitys most immediate healthcare needs, said Sam Reiman, Director of the Richard King Mellon Foundation.
  • Its an honor to be selected for this funding from the Richard King Mellon Foundation, said Teresa Whalen, RPh , CEO, CytoAgents.
  • The $250,000 investment will accelerate the development of GP1681, which will be going into Phase 1 and Phase 2 human clinical trials in 2020.
  • Founded in 1947, the Richard King Mellon Foundation is the largest foundation in southwestern Pennsylvania.

Global Hospital Acquired Infection (HAI) Control Market 2020-2027 - Radiation Sterilization Equipment Corners a 19.8% Share in 2020 - ResearchAndMarkets.com

Tuesday, July 7, 2020 - 11:00am

The "Hospital Acquired Infection Control - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hospital Acquired Infection Control - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • This segment currently accounts for a 25.9% share of the global Hospital Acquired Infection Control market.
  • The U. S. Accounts for Over 27% of Global Market Size in 2020, While China is Forecast to Grow at a 6% CAGR for the Period of 2020-2027
    The Hospital Acquired Infection Control market in the U. S. is estimated at US$1.5 Billion in the year 2020.
  • In the global Radiation Sterilization Equipment segment, USA, Canada, Japan, China and Europe will drive the 2.5% CAGR estimated for this segment.

ChromaDex and the NIH-NIAID Rocky Mountain Laboratories Announce Study to Assess the Therapeutic Potential of Niagen® in COVID-19 Animal Models

Tuesday, July 7, 2020 - 11:34am

This study will assess if administration of Niagen (nicotinamide riboside, or NR) can reduce viral burden and inflammation in mouse and hamster models of COVID-19.

Key Points: 
  • This study will assess if administration of Niagen (nicotinamide riboside, or NR) can reduce viral burden and inflammation in mouse and hamster models of COVID-19.
  • ChromaDexs patent-protected NR is a unique nutrient that supports cellular energy production and healthy mitochondrial function through efficient restoration of NAD+ levels.
  • The study is part of the ChromaDex External Research Program (CERP) in which ChromaDexs NR ingredient and placebos are provided to researchers at no cost.
  • The study will be conducted at the Rocky Mountain Labs (RML) of the NIH-NIAID.

New APM Study Reveals the Contribution of Projects and Project Management in the Health, Pharmaceutical and Life Sciences Sector

Tuesday, July 7, 2020 - 9:00am

APM identified the healthcare sector (incorporating pharmaceutical and life sciences) as a key area of growth and professionalisation of project management.

Key Points: 
  • APM identified the healthcare sector (incorporating pharmaceutical and life sciences) as a key area of growth and professionalisation of project management.
  • However, it is often the case that project teams are led by staff with no formal training in project management.
  • A lack of awareness of project management can increase the challenge of justifying investment in project management techniques.
  • Misconceptions of project management - The study highlights how there are common misperceptions of project management across the health sectors, often due to negative experiences of poor project implementation.